Jan. 16, 2020: Texting (and stigma support) vs. email for care retention; beyond-childhood health risks for HIV-exposed infants; HIV, cardiovascular risk, and cognitive impairment; direct-acting antiviral efficacy and prescription delays.
While it is too soon to tell, this research involving broadly neutralizing antibodies could point to new methods for preventing vertical transmission.
In this op-ed, a group of family physicians and HIV specialists revisit the cruel reality happening at the U.S. border for people living with HIV.
The vaccine for human papillomavirus got a bad rap when it debuted. And yet time has shown it's very effective in reducing cancers linked to HPV.
Young people in the nation's capital are living in the middle of some of the worst structural and systemic inequalities in America. We should be helping them out.
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
Bridgette Brawner, Ph.D., APRN, was recently honored for her research on heterosexually active black teens with mental illness -- a group that's under-represented in HIV prevention campaigns.
Kistin Nolan, M.P.H., and colleagues helped pilot a retention program designed to accommodate the emotional turmoil that makes it more difficult for young people with HIV to successfully navigate the health care system.